CA-SENSEFORTH.AI
Conversational AI leader Senseforth.ai today announced a $14 million investment from Fractal (fractal.ai ), a global provider of artificial intelligence and analytics solutions to Fortune 500® companies. This investment will help Senseforth.ai scale and expand its footprint across Fractal’s clients globally. This investment also strengthens Fractal's conversational AI offerings as it advances on its mission to power every human decision in the enterprise.
Senseforth.ai’s patented and award winning zero-code platform A.ware automates customer experience across digital touchpoints for global enterprises. It is estimated that by 2022, 30% of customer experiences will be handled by conversational AI, up from 3% in 2017. A.ware makes it easy to build, train, deploy, and scale conversational AI solutions to drive revenue, reduce costs and increase operational efficiency.
Shridhar Marri, CEO and Co-Founder of Senseforth said, “This strategic investment creates a new growth blueprint for Senseforth.ai. We are thrilled to deliver on our vision 'to make technology humanlike', enabling continuous Human-AI interaction and transforming complex business processes.” He added, “We can now scale talent, accelerate growth, make more investments in R&D, and create incredible value for our clients.”
Announcing the strategic investment, Fractal’s Co-Founder, Group Chief Executive and Vice Chairman, Srikanth Velamakanni said, “Senseforth.ai’s founders Shridhar, Krishna and Ritesh have built a great team and a robust platform that’s deployed at scale with marquee clients like HDFC Bank. Senseforth’s technology is ahead of the competition, especially as evidenced by their performance benchmark on the leaderboard of Stanford Question Answering Dataset (SQuAD) 2.0.” Srikanth added, “We are excited to partner with the Senseforth.ai team to contribute to their next phase of growth.”
“We are inspired by Senseforth.ai’s work with the government of India to remove technology barriers in accessing citizen services for 700 million internet users through conversational AI. We are delighted to partner with Senseforth and expand conversational AI solutions to our clients,” said Pranay Agrawal, Fractal’s Co-founder and Chief Executive Officer.
Krishna Kadiri, Chief AI Officer and Co-Founder of Senseforth said, “Senseforth has a robust R&D and innovation culture and has already made its mark in the global ML benchmarks. This investment will help us enhance our deep learning capabilities and embed advanced cutting-edge research into A.ware.”
Don Vadakan, Chief Sales Officer at Fractal said, “Senseforth’s industry agnostic, multi-experience AI platform will drive next-generation digital solutions. We are excited to deliver powerful use cases across industries for both large and mid-size enterprises with A.ware from Senseforth.”
Ritesh Radhakrishnan, CTO, and Co-Founder of Senseforth said, “At Senseforth.ai, we have built A.ware, one of the most powerful and comprehensive Conversational AI Platforms in the market today. A.ware is already automating billions of conversations for enterprises across the world. This investment will help us further strengthen our technology foundation and scale our platform and products to become the undisputed market leader in the Conversational AI space.”
About Senseforth.ai
Senseforth.ai is a Conversational AI platform that enables automated human-like conversations at scale, between organizations and people. Founded with a vision to “make technology humanlike”, Senseforth.ai helps businesses acquire, engage and assist customers using AI-powered bots. As a preferred partner of choice for enterprises in North America, Europe and APAC, Senseforth.ai has implemented 100+ solutions that handle millions of conversations every month and has been recognized as a ‘Cool Vendor’ in Conversational AI Platforms in 2020 by Gartner, For more information, visit www.senseforth.ai
About Fractal
Fractal is one of the leading providers of AI and analytics globally to the world's most admired Fortune 500® companies. Fractal's mission is to power every human decision in the enterprise by bringing AI, engineering, and design to solve some of the world’s toughest problems.
Fractal's products include Qure.ai, to assist radiologists in making better diagnostic decisions; Crux Intelligence, to assist CEOs, and senior executives make better tactical and strategic decisions; Theremin.ai, to improve investment decisions; Eugenie.ai, to find anomalies in high-velocity data; and Samya.ai to drive next generation enterprise revenue growth management.
Fractal has more than 2,800 employees across 16 global locations, including the United States, UK, Ukraine, India, Singapore and Australia. Fractal has consistently been rated among India's best companies to work for, by The Great Place to Work® Institute; featured as a leader in the Customer Analytics Service Providers Wave™ 2021, Specialized Insights Service Providers Wave™ 2020 & Computer Vision Consultancies Wave™ 2020, by Forrester Research; and recognized as an "Honorable Vendor" in 2021 Magic Quadrant™ for data & analytics by Gartner. For more information visit fractal.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005361/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom